Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca Buys AlphaCore Pharma

by Michael McCoy
April 8, 2013 | A version of this story appeared in Volume 91, Issue 14

MedImmune, AstraZeneca’s biologics drug unit, has acquired AlphaCore Pharma, an Ann Arbor, Mich.-based biotech company that is developing ACP-501, a recombinant human lecithin-cholesterol acyltransferase enzyme, as a cholesterol management agent. Several AlphaCore scientists were part of the team that discovered the Pfizer cholesterol drug Lipitor. The deal is AstraZeneca’s first acquisition since new CEO Pascal Soriot laid out a revamp plan for the company last month.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.